Drugs / PEG-EPO
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05629598 | Apr 2022 → Mar 2023 | anemia | Angde Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-EPO | “The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the...” NCT05629598 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Recombinant human erythropoietin injection” NCT05629598 ↗ |